-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text | pick up shells
On July 6, the CDE official website showed that the clinical application of AstraZeneca's second-generation PARP (highly selective PARP1) inhibitor AZD5305 has been accepted by the State Food and Drug Administration
Since olaparib was approved for BRCA-mutated (BRCAm) ovarian cancer in 2014, a variety of PARP inhibitors have been developed and have achieved widespread success
Most of the first-generation PARP inhibitors were developed and optimized before the concept of PARP1-DNA capture was discovered, which is the mechanism by which PARP inhibitors exert a synthetic lethal effect on BRCAm cells
Therefore, researchers began to look for the best-in-class second-generation PARP inhibitors, that is, among the other 16 members of the PARP family, they are highly selective for PARP1 and are also highly effective PARP1-DNA traps
The amino acid sequences of PARP1 and PARP2 are highly similar, and most of the residues around the nicotinamide binding site are the same
At the 2021 AACR annual meeting, AstraZeneca announced the preclinical data of AZD5305
At the same time, AZD5305 also showed benefits when used in combination with chemotherapy
On November 25, 2020, AstraZeneca published a phase I clinical trial (NCT04644068) on the ClinicalTrials.
Original title: AstraZeneca's second-generation PARP inhibitor AZD5305 has been applied for clinical application
